Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BrUOG-E-215-neoadjuvant paclitaxel poliglumex (PPX; CT-2103), cisplatin and radiation for esophageal cancer: a phase II trial (CTIX64001)

Next Previous
X
Search
Trial Profile

BrUOG-E-215-neoadjuvant paclitaxel poliglumex (PPX; CT-2103), cisplatin and radiation for esophageal cancer: a phase II trial (CTIX64001)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Paclitaxel poliglumex (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 25 Feb 2011 Results published in the American Journal of Clinical Oncology, according to a Cell Therapeutics media release.
    • 26 May 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
    • 24 May 2010 Results will be presented at the American Society of Clinical Oncology 2010 Annual Meeting, according to a Cell Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top